Cyclo Therapeutics- Warrants (14/11/2025) Profit Margin

Cyclo Therapeutics- Warrants (14/11/2025) (CYTHW) currently reports a profit margin of -2848.16% as of September 2024. That compares with -2019.93% in the prior-year period — down 41.0% year over year. That is below the Healthcare sector average of 14.34%. Use the charts on this page to explore Cyclo Therapeutics- Warrants (14/11/2025)'s profit margin history and peer comparisons.

Cyclo Therapeutics- Warrants (14/11/2025)'s profit margin decreased from -2019.93% to -2848.16% — a 41.0% year-over-year decrease (period ending September 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Cyclo Therapeutics- Warrants (14/11/2025)'s profit margin of -2848.16% is lower than the Healthcare sector average of 14.34%. That is roughly 19955.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Cyclo Therapeutics- Warrants (14/11/2025)'s current -2848.16% should be judged against Healthcare norms (sector average: 14.34%) and against CYTHW's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -2848.16%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 14.34%. From there, open related valuation or income-statement pages for Cyclo Therapeutics- Warrants (14/11/2025), and consider following CYTHW for alerts when major investors trade the stock.